Tesaro Inc. (TSRO) Expected to Earn FY2017 Earnings of ($5.25) Per Share
Tesaro Inc. (NASDAQ:TSRO) – Investment analysts at Leerink Swann lifted their FY2017 EPS estimates for Tesaro in a research note issued on Sunday. Leerink Swann analyst S. Fernandez now expects that the firm will post earnings of ($5.25) per share for the year, up from their previous forecast of ($5.38). Leerink Swann currently has a “Outperform” rating and a $115.00 target price on the stock. Leerink Swann also issued estimates for Tesaro’s FY2018 earnings at $0.10 EPS and FY2019 earnings at $4.87 EPS.
Tesaro (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.43. The firm earned $36.60 million during the quarter, compared to analysts’ expectations of $4.98 million. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. During the same quarter last year, the business posted ($1.51) EPS.
A number of other research analysts have also issued reports on TSRO. Mizuho reiterated an “outperform” rating and set a $67.00 price target on shares of Tesaro in a research report on Thursday, June 30th. Lake Street Capital reiterated a “buy” rating and set a $114.00 price target on shares of Tesaro in a research report on Tuesday, September 6th. Robert W. Baird boosted their price target on Tesaro from $105.00 to $120.00 and gave the stock an “outperform” rating in a research report on Monday. FBR & Co reiterated a “buy” rating on shares of Tesaro in a research report on Thursday, June 30th. Finally, Wells Fargo & Co. reiterated an “outperform” rating on shares of Tesaro in a research report on Thursday, June 30th. One analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company’s stock. Tesaro presently has a consensus rating of “Buy” and a consensus price target of $110.11.
Tesaro (NASDAQ:TSRO) traded up 1.20% during mid-day trading on Wednesday, reaching $116.15. The company had a trading volume of 1,075,904 shares. The stock’s 50-day moving average is $98.16 and its 200 day moving average is $70.43. Tesaro has a 12 month low of $29.51 and a 12 month high of $122.89. The firm’s market capitalization is $5.97 billion.
A number of hedge funds and other institutional investors have recently bought and sold shares of TSRO. CenturyLink Investment Management Co acquired a new position in Tesaro during the third quarter valued at $172,000. KCG Holdings Inc. acquired a new position in Tesaro during the second quarter valued at $228,000. Quantitative Systematic Strategies LLC acquired a new position in Tesaro during the second quarter valued at $240,000. Bluestein R H & Co. acquired a new position in Tesaro during the second quarter valued at $252,000. Finally, Neuberger Berman Group LLC acquired a new position in Tesaro during the second quarter valued at $256,000. 88.81% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Martin H. Jr. Huber sold 408 shares of the company’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total transaction of $44,112.96. Following the transaction, the senior vice president now directly owns 1,250 shares of the company’s stock, valued at $135,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jeffrey H. Hanke sold 29,166 shares of the company’s stock in a transaction on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total value of $2,509,442.64. Following the transaction, the vice president now directly owns 29,166 shares in the company, valued at $2,509,442.64. The disclosure for this sale can be found here. Insiders own 40.50% of the company’s stock.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.